Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03113643
Recruitment Status : Recruiting
First Posted : April 13, 2017
Last Update Posted : September 18, 2019
Sponsor:
Collaborator:
Stemline Therapeutics, Inc.
Information provided by (Responsible Party):
Andrew Lane, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : May 31, 2023